Programmed cellular immunotherapeutic - Fate Therapeutics

Next Previous
Drug Profile

Programmed cellular immunotherapeutic - Fate Therapeutics

Alternative Names: FT1050/FT4145 - modulated mobilised peripheral blood; Programmed mobilised peripheral blood cells; ProTmune; ProTmune FT1050/FT4145 programmed mobilised peripheral blood

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Scripps Research Institute
  • Developer Fate Therapeutics
  • Class Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cytomegalovirus infections; Graft-versus-host disease

Most Recent Events

  • 11 Dec 2017 Efficacy and adverse events data from Phase I/II PROTECT trial in Graft-versus-host disease and Cytomegalovirus infections presented at the 59th American Society of Hematology Annual Meeting and Exposition (ASH-2017)
  • 18 Sep 2017 Phase-II clinical trials in Graft-versus-host disease and Cytomegalovirus infections (Prevention) in USA
  • 07 Oct 2016 Fate Theraeputics receives patent allowance for Programmed cellular immunotherapeutic in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top